NEXT Oncology and Virginia Cancer Specialists have joined forces, launching NEXT Virginia, a cancer clinic, in September 2021. This partnership will also help expand VCS’s phase I and developmental therapeutics cancer research program and bring the latest in new agents and anticancer treatments to the VCS Research Institute. The expanded phase I program will begin this fall, while the stand-alone …

Nicole Villalpando Austin American-Statesman – view article Lynne Xavier, 55, remembers when her husband was part of clinical trials for rectal cancer at MD Anderson in Houston.  “Watching him to go back and forth and back and forth and the wear on him,” she said, made the Austinite decide not to participate in any clinical trials out of town when she was …

Next Oncology is advancing plans to expand its clinical trials facilities footprint nationally and internationally despite a global health crisis impacting that timeline. The San Antonio-based cancer research company has recently opened the first such facility outside of its headquarters home and already has other centers in various stages of development. “The next 12 months are going to be absolutely …

Last month, the FDA granted accelerated approval of sotorasib (Lumakras) for the treatment of adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), following the results of the phase II CodeBreaK 100 trial, data from which were presented during the recent virtual American Society of Clinical Oncology annual meeting. In this second of four exclusive episodes, MedPage Today brought together three leaders in the field —  moderator Vinay Prasad, MD, …

— Our expert roundtable discusses how they the treat NSCLC patients who are waiting on NGS results Next-generation sequencing (NGS) is recommended by the National Comprehensive Cancer Network (NCCN) for all patients with non-small cell lung cancer (NSCLC). Several studies at the recent American Society of Clinical Oncology virtual annual meeting explored the application of biomarker testing in the U.S., as well …

At the recent virtual American Society of Clinical Oncology annual meeting, results of the phase III IMpower010 trial demonstrated that adjuvant atezolizumab (Tecentriq) for patients with stage IB to IIIA non-small cell lung cancer (NSCLC) improved disease-free survival in patients with high PD-L1 expression. In this first of four exclusive episodes, MedPage Today brought together three leaders in the field —  moderator Vinay Prasad, MD, of the University …

Dr. Anthony Tolcher’s dedication to medical advancements and innovative approaches at NEXT Oncology has earned the practice Best Oncologist in San Antonio in the 2021 Readers’ Choice Awards. NEXT Oncology has made strides in patient care, especially over the past year. As a Phase 1 research center, patient safety is critical. Patients on clinical trials are faced with even greater …

NATIONAL HARBOR, Md. — A novel immunomodulatory therapy demonstrated antitumor activity across a broad range of heavily pretreated, immunotherapy-resistant tumors, including objective responses in advanced non-small cell lung cancer (NSCLC), a preliminary study showed. Treatment with the Siglec-15-targeted monoclonal antibody NC318 led to disease control (response and stable disease) in one-third of the 49 patients on study. The activity included …

Next Oncology, launched a year ago in San Antonio, is moving its headquarters to the Christus Santa Rosa Hospital-Medical Center campus as the phase I cancer research organization advances plans for expansion in the U.S. and abroad. Next Oncology has signed an 11-year lease for nearly 20,000 square feet at Christus’ Medical Center Tower I. It was initially operating in …